Clinical trial · Observational
Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan
Observational Study of Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan
NCT00867633CI-TRIAL-00006313unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the association between aristolochic acid and urothelial carcinoma in Taiwan
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Urothelial carcinoma
- description
- The DNA samples extracted from the urothelial carcinoma tissue
- label
- RCC
- description
- the DNA sample extracted from RCC
- label
- Non-cancer
- description
- The DNA sample extracted from the non-cancerous kidney tissue
Primary outcomes (1)
- measure
- the incidence of aristolochic-acid DNA adduct in the samples
- timeFrame
- one week
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * the resected kidney tissue in the tissue bank Exclusion Criteria: * the patients who had been ever exposed to arsenics, rubber, chemicals, irradiation for pelvis, or received chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.